These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26155391)

  • 41. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy.
    Li H; Wang Z; Zhang Y; Sun G; Ding B; Yan L; Liu H; Guan W; Hu Z; Wang S; Cheng F; Xu H; Zhang X; Ye Z
    J Cancer; 2019; 10(14):3102-3111. PubMed ID: 31289580
    [No Abstract]   [Full Text] [Related]  

  • 44. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
    Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
    JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
    Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
    Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
    Boudin L; De Nonneville A; Finetti P; Guittard G; Nunes JA; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma.
    Chen Z; Deng X; Ye Y; Zhang W; Liu W; Zhao S
    Front Oncol; 2021; 11():687911. PubMed ID: 34211855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk stratification systems for surgically treated localized primary Gastrointestinal Stromal Tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogramm, NIH-Fletcher and AFIP-Miettinen.
    Belfiori G; Sartelli M; Cardinali L; Tranà C; Bracci R; Gesuita R; Marmorale C
    Ann Ital Chir; 2015; 86(3):219-27. PubMed ID: 26098671
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.
    Koumarianou A; Economopoulou P; Katsaounis P; Laschos K; Arapantoni-Dadioti P; Martikos G; Rogdakis A; Tzanakis N; Boukovinas I
    Biomark Cancer; 2015; 7(Suppl 1):1-7. PubMed ID: 26056505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
    Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
    Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker.
    Yen CC; Yeh CN; Cheng CT; Jung SM; Huang SC; Chang TW; Jan YY; Tzeng CH; Chao TC; Chen YY; Yang CY; Ho CL; Fletcher JA
    Ann Surg Oncol; 2012 Oct; 19(11):3491-9. PubMed ID: 22588468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.
    Ott E; Bilonda L; Dansette D; Deleine C; Duchalais E; Podevin J; Volteau C; Bennouna J; Touchefeu Y; Fourquier P; El Alami Thomas W; Chetritt J; Bezieau S; Denis M; Toquet C; Mosnier JF; Jarry A; Bossard C
    Oncoimmunology; 2019; 8(4):e1562834. PubMed ID: 30906656
    [No Abstract]   [Full Text] [Related]  

  • 57. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.
    Ma H; Yang W; Zhang L; Liu S; Zhao M; Zhou G; Wang L; Jin S; Zhang Z; Hu J
    Br J Cancer; 2019 Feb; 120(3):317-330. PubMed ID: 30555157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
    Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
    [No Abstract]   [Full Text] [Related]  

  • 60. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.